journal article·2016

Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours

A. Martirosyan, M. J. Olesen, R. A. Fenton, J. Kjems, K. A. Howard

Nanoscale· Volume 8· Issue 25
Publisher page

Abstract

This work demonstrates gastric mucin-triggered nanocarrier disassembly for release of antisense oligonucleotides and consequent unassisted cellular entry as a novel oral delivery strategy. A fluorescence activation-based reporter system was used to investigate the interaction and mucin-mediated disassembly of chitosan-based nanocarriers containing a 13-mer DNA oligonucleotide with a flanked locked RNA nucleic acid gapmer design. Gastric mucins were shown to trigger gapmer release from nanocarriers that was dependent on the interaction time, mucin concentration and N : P ratio with a maximal release at N : P 10. In contrast to siRNA, naked gapmers exhibited uptake into mucus producing HT-MTX mono-cultures and HT-MTX co-cultured with the carcinoma epithelial cell line Caco-2. Importantly, in vivo gapmer uptake was observed in epithelial tissue 30 min post-injection in murine intestinal loops. The findings present a mucosal design-based system tailored for local delivery of oligonucleotides that may maximize the effectiveness of gene silencing therapeutics within tumours at mucosal sites.
Source: openalex_inverted_index · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Glycosylation and Glycoproteins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Interdisciplinary Nanoscience Center (iNANO)

Department of Molecular Biology and Genetics

Aarhus University

Aarhus C, Denmark

Department of Biomedicine

Funding

Strategiske Forskningsrad

References (46)

Show source-provided references
1. Cancer Classification of the National Cancer Institute, http://training.seer.cancer.gov/disease/categories/classification.html
2. Malvezzi · Ann. Oncol. · 2015 · 1
3. Miele · Int. J. Nanomed. · 2012 · 7 · 3637
4. Ballarín-González · Cancer Lett. · 2014 · 352 · 6610.1016/j.canlet.2013.09.023 ↗
5. Wu · Sci. Transl. Med. · 2014 · 6 · 240ps710.1126/scitranslmed.3008362 ↗
6. Howard · Expert Opin. Biol. Ther. · 2007 · 7 · 181110.1517/14712598.7.12.1811 ↗
7. Howard · Adv. Drug Delivery Rev. · 2009 · 61 · 71010.1016/j.addr.2009.04.001 ↗
8. Olsesen · Drug Delivery Transl. Res. · 2014 · 4 · 410.1007/s13346-013-0156-9 ↗
9. Linden · Mucosal Immunol. · 2008 · 1 · 18310.1038/mi.2008.5 ↗
10. Lai · Adv. Drug Delivery Rev. · 2009 · 61 · 8610.1016/j.addr.2008.09.012 ↗
11. Bansil · Front. Immunol. · 2013 · 310
12. Draz · Theranostics · 2014 · 4 · 87210.7150/thno.9404 ↗
13. Illum · Adv. Drug Delivery Rev. · 2001 · 51 · 8110.1016/S0169-409X(01)00171-5 ↗
14. Martirosyan · Adv. Genet. · 2014 · 88 · 32510.1016/B978-0-12-800148-6.00011-0 ↗
15. Howard · Mol. Ther. · 2006 · 14 · 47610.1016/j.ymthe.2006.04.010 ↗
16. Liu · Biomaterials · 2007 · 28 · 128010.1016/j.biomaterials.2006.11.004 ↗
17. Nielsen · Pharm. Res. · 2010 · 27 · 252010.1007/s11095-010-0255-y ↗
18. Ballarín-González · Mol. Ther. Nucleic Acids · 2013 · 2 · e7610.1038/mtna.2013.2 ↗
19. Thomsen · Nanoscale · 2014 · 6 · 1254710.1039/C4NR01584C ↗
20. Stein · Nucleic Acids Res. · 2010 · 38 · e310.1093/nar/gkp841 ↗
21. Moschos · Mol. Ther. · 2011 · 19 · 216310.1038/mt.2011.206 ↗
22. Wahlestedt · Proc. Natl. Acad. Sci. U. S. A. · 2000 · 97 · 563310.1073/pnas.97.10.5633 ↗
23. Castanotto · Curr. Opin. Oncol. · 2014 · 26 · 58410.1097/CCO.0000000000000127 ↗
24. Moreno · Front. Chem. · 2014 · 2 · 8710.3389/fchem.2014.00087 ↗
25. Martirosyan · Nanotoxicology · 2014 · 8 · 57310.3109/17435390.2013.812258 ↗
26. The International Pharmacopoeia, 5th edition http://apps.who.int/phint/en/p/docf/
27. Andersen · Methods Mol. Biol. · 2009 · 555 · 7710.1007/978-1-60327-295-7_6 ↗
28. Moeller · Kidney Int. · 2009 · 75 · 29510.1038/ki.2008.505 ↗
29. Matsuo · Gut · 1997 · 40 · 78210.1136/gut.40.6.782 ↗
30. Zhou · J. Am. Chem. Soc. · 2012 · 134 · 780310.1021/ja300176w ↗
31. Ho · J. Mater. Chem. B · 2013 · 1 · 242510.1039/c3tb20146e ↗
32. De Campos · Eur. J. Pharm. Sci. · 2003 · 20 · 7310.1016/S0928-0987(03)00178-7 ↗
33. Mahler · J. Nutr. Biochem. · 2009 · 20 · 49410.1016/j.jnutbio.2008.05.006 ↗
34. Kurreck · Nucleic Acids Res. · 2002 · 30 · 191110.1093/nar/30.9.1911 ↗
35. Ensign · Adv. Mater. · 2012 · 24 · 388710.1002/adma.201201800 ↗
36. Okamoto · J. Gastroenterol. · 2004 · 39 · 110.1007/s00535-003-1259-8 ↗
37. Niebel · J. Controlled Release · 2012 · 160 · 65910.1016/j.jconrel.2012.03.004 ↗
38. Lautenschlager · Eur. J. Pharm. Biopharm. · 2013 · 85 · 57810.1016/j.ejpb.2013.09.016 ↗
39. Wilson · Nat. Mater. · 2010 · 9 · 92310.1038/nmat2859 ↗
40. Prados · BioDrugs · 2013 · 27 · 31710.1007/s40259-013-0019-4 ↗
41. Kufe · Nat. Rev. Cancer · 2009 · 9 · 87410.1038/nrc2761 ↗
42. Debunne · Acta Chir. Belg. · 2013 · 113 · 38510.1080/00015458.2013.11680951 ↗
43. Torres · Curr. Pharm. Des. · 2012 · 18 · 247210.2174/13816128112092472 ↗
44. Roulois · BioMed Res. Int. · 2013 · 871936
45. Horm · Cell Adhes. Migr. · 2013 · 7 · 18710.4161/cam.23131 ↗
46. Spicer · J. Biol. Chem. · 1995 · 270 · 3009310.1074/jbc.270.50.30093 ↗